TNF inhibitor
![](https://pbs.twimg.com/profile_images/1659729373426241536/tnA2hRe4.jpg)
1 year 3 months ago
Malignancy in real world datasets:
do we see differences between DMARDs - particularly JAKi, with ORAL Surveillance in mind?
RABBIT German data (limited risk window):
Point estimates slightly up vs TNFi, esp in high CV risk pts
but magnitude not big
OP0218 #EULAR2023 @RheumNow https://t.co/Ou7TgWvf3b
![](https://pbs.twimg.com/media/FxmuriOaUAAwGCd.jpg)
![](https://pbs.twimg.com/profile_images/1659729373426241536/tnA2hRe4.jpg)
1 year 3 months ago
Just a reminder: nr-axSpA isn’t destined to become r-axSpA/AS. Life is more complicated than that.
Between the natural history and TNFi, very small conversion rate post-10y. Of course, whatever the x-rays, it can still disable though
DESIR cohort POS0675 #EULAR2023 @RheumNow https://t.co/29HeJXpK2S
![](https://pbs.twimg.com/media/FxiTmEraMAAyGQY.jpg)
![](https://pbs.twimg.com/profile_images/1463469865382125579/asKzXYsY.jpg)
1 year 3 months ago
TNFi & Disease activity-guided dose optimization in RA⬇️prog of ADA or ETA daily dose (100%66%50%0%)
10yrs followup in 170pts
⭐️74% tapered until full discontinuation
⭐️Median time to restart 8 mo
⭐️21% never restarted!
What's lacking? % of recovery
@Rheumnow OP0131 #EULAR23 https://t.co/Ms6lqQ7cWf
![](https://pbs.twimg.com/media/FxiAuPIWcAAumRS.png)
![](https://pbs.twimg.com/profile_images/1463469865382125579/asKzXYsY.jpg)
1 year 3 months ago
CareRA trial:
3 months addition of LEF vs. ETA in pts resistant to COBRA-Slim regimen (MTX 15 mg/w + step-down prednisone):
After 2 years, no difference in dis control but those who received ETA early were treated more frequently w/ csDMARD monotherapy #EULAR23 @RheumNow OP0129 https://t.co/YwSoZWi375
![](https://pbs.twimg.com/media/Fxh-lZKXsAEPfZR.png)
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE.jpg)
1 year 3 months ago
The risk of demyelination with TNFi is low but real. Slight increase of risk was found in male RA patients. The small number of events is reassuring. Careful consideration is recommended in individuals at highest risk of demyelinating diseases Abst#OP0135 #EULAR2023 @RheumNow https://t.co/YT6ZrJTjU0
![](https://pbs.twimg.com/media/Fxh3DdzWwAQQQ-j.jpg)
![](https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC_.jpg)
1 year 3 months ago
#EULAR2023 #OP0142 From #Lupus to #Sjogren. A phase 2 RCT in China showed more patients on Telitacicept (BAFF/APRIL-i) achieved significant reduction in ESSDAI at Wk24 vs PBO. Trend to improvement in glandular function. Intriguing option & will await Phase 3 global RCT @RheumNow https://t.co/BCiohuAfP3
![](https://pbs.twimg.com/media/Fxhxj74WAAQFA-E.jpg)
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE.jpg)
1 year 3 months ago
JAKi have superior effectiveness at 6 months compared to TNFi and the efficacy was similar in those with and and without safety risk (increased age, CV risk, smoker) by Hannah Bower, Abst#0133 #EULAR2023 @RheumNow https://t.co/Pt6EoN6323
![](https://pbs.twimg.com/media/FxhxmgyWYAAlXsh.jpg)
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE.jpg)
1 year 3 months ago
The overall risk of cancer and cardiovascular disease were decreased in RA treated with JAKi but there was no comparison with TNFi, Sung Soo Ahn, Abst#00132 #EULAR2023 @RheumNow https://t.co/9Bi6t6uuig
![](https://pbs.twimg.com/media/FxhvHv9WIAAeZ_H.jpg)
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE.jpg)
1 year 3 months ago
Biologic dose reduction based on disease activity resulted in 40% reduction in TNFi and did not seem to cause disease deterioration from the 10 year DRESS Study by N van Herwaarden, Abst#OP00131 #EULAR2023 @RheumNow https://t.co/ncGPF9ODcF
![](https://pbs.twimg.com/media/FxhsowIWIAI4LtN.jpg)
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE.jpg)
1 year 3 months ago
In insufficient responders, additional Etanercept for 24 weeks (bio-induction) did not show a higher response of DAS28-CRP compared to the standard COBRA-SLIM regime from the CARERA2020 study by Delphine Bertrand, Abstr#00129 #EULAR2023 @RheumNow https://t.co/BR1GusPGRP
![](https://pbs.twimg.com/media/Fxhn79SXoAE5Ktu.jpg)